For questions regarding claiming CME Credit, please refer to our FAQ section.

 

 

Post ACC 2016 Banner CME Page

Program Overview:

New data from the PARTNER 2A trial and the SAPIEN 3 trial and the benefits to intermediate risk patients will be discussed in detail during this webcast. This subset of intermediate risk patients receiving transcatheter aortic valve replacement (TAVR) have less risk of stroke and mortality than those receiving surgery. Patient selection, the importance of heart teams, and center experience improve patient outcomes. These two trials will establish the benefits of TAVR to the intermediate risk population and how the future of TAVR will change with more trials and use in low risk patients.        read more...  

Click Here to access this CME Program   
Release Date:
April 8th, 2016

Expiration Date:
October 8th, 2016 

Estimated Time:
1 hour    

  
 

 

Post AHA Banner

Program Overview:

The Appropriate Use Criteria (AUC) was developed to review the expected health benefits of a procedure outweigh the expected health risks. According to earlier studies Percutaneous Coronary Intervention (PCI) was performed for non-acute indications inappropriately. In a comprehensive review of patients undergoing PCI between July 2009 and December 2014, the AUC examined the indications, angiographic findings, symptoms, ischemia and background medical therapy to determine the appropriateness of PCI. Over 2.7 million PCI procedures and 766 hospitals were included.        read more... 

Click Here to access this CME Program   
Release Date:
March 23rd, 2016

Expiration Date:
September 23rd, 2016 

Estimated Time:
1 hour    



  
Recent TAVR Updates and Upcoming Studies at ACC 2016 - Banner 200

Program Overview:

During this webcast, there will be a comprehensive discussion on five separate topics involving TAVR and the benefits to patients. Data from the PARTNER II trial, the SAPIEN 3 trial, and the BRAVO 3 trial, which questions the use of bivalirudin as an alternative to heparin, will be discussed. The other two informative discussions will cover the use of 4-D CT and the cardiac function of patients undergoing valve replacements and the use of warfarin to decrease thrombosis. The webcast will address upcoming trials and data that will help the viewer identify changes to and improvements of TAVR in the future.  read more... 

Click Here to access this CME Program   
Release Date:
March 4th, 2016

Expiration Date:
September 4th, 2016 

Estimated Time:
1 hour    



Post TCT 2015 - Banner

Program Overview:

In a double-bind randomized study of 2.466 patients at high risk of bleeding, using 1 month of dual antiplatelet therapy (DAPT) and the BioFreedom polymer-free BiolimusA9 (BA9) drug-coated stents (DCS) is safer and more effective than using a bare metal stent (BMS).   The LEADERS FREE trial included a subset of patients normally excluded from studies due to higher co-morbidities and higher event rates. This group was evaluated on the incidence of myocardial infarction, cardiac death and stent thrombosis as a primary endpoint .The difference in MI and cardiac death was lower in those receiving a DCS. Patients requiring target lesion revascularization was decreased in those with the use of DCS and DAPT for 1 month. read more...

Click Here to access this CME Program   
Release Date:
January 22, 2016

Expiration Date:
July 22, 2016 

Estimated Time:
1 hour    
 
 
Volcano Banner 200x100

Program Overview:

Atrial fibrillation, a condition affecting millions of patients worldwide, is associated with increased risks of stroke and mortality that complicate the risk-benefit profile of patients who undergo PCI. Management options include not only warfarin but also a growing array of novel anticoagulants that aim to reduce the need for monitoring and improve safety and efficacy. read more...


Click Here to access this CME Program   
Release Date:
November 20th, 2015

Expiration Date:
May 20th, 2016 

Estimated Time:
1 hour    
 


Post ESC 2015 Banner: MATRIX Duration, OPTIDUAL and PLATFORM

Program Overview:

Current controversies, such as the choice of antithrombin during PCI, the duration of dual antiplatelet therapy (DAPT), and the identification of PCI candidates among stable CAD patients, will be explored during this one-hour webcast. The MATRIX Treatment Duration study compared outcomes with of bivalirudin and heparin use among 7,000 European ACS patients and also examined the impact of post- PCI bivalirudin infusion. Next, the OPTIDUAL trial examined the impact of DAPT use for up to 4 years after PCI in patients free of adverse events in the first year. Finally, the PLATFORM study examined the utility of CT-derived FFR for patients with stable coronary artery disease. read more...


Click Here to access this CME Program   
Release Date:
November 23, 2015

Expiration Date:
May 23, 2016 

Estimated Time:
1 hour